BRAF and non-small cell lung carcinoma: While the higher frequency of using molecular tests in non-squamous NSCLC and NOS versus the entire group was observed for established mutations, the differences for emerging mutations such as RET, NTRK, BRAF, HER2, and MET were negligible (approx. 10% in both groups).